#USA #Atlanta #oncology #Real-World Data #OMNY Health

OMNY Health Reaches 175 Million Patient Mark

In a significant development for the healthcare data landscape, OMNY Health has announced its expansion to encompass over 175 million de-identified longitudinal patient records, effectively covering nearly half of the U.S. population. This remarkable milestone establishes OMNY Health as the largest commercial source of first-party, provider-driven clinical Real-World Data (RWD) in the nation.

The recent growth trajectory of OMNY Health has been achieved through strategic expansions involving Integrated Delivery Networks (IDNs), community hospitals, Academic Medical Centers (AMCs), and substantial multi-state specialty groups. By sourcing data directly from point-of-care, OMNY provides an unrivaled perspective into diverse patient journeys on a national scale, paving the way for deeper insights into healthcare practices and patient outcomes.

Bridging Gaps in Cancer Research

Aligned with this expansive network growth, OMNY Health has introduced the OMNY Foundation Oncology, a tailored product suite aimed at addressing critical data deficiencies in cancer research. Traditional datasets frequently overlook crucial context surrounding pre-diagnosis and post-treatment phases, yet OMNY's initiative seeks to capture comprehensive insights from patient experiences across over 10 million oncology patient journeys dating back to 2017.

The oncology product suite adeptly merges structured Electronic Health Record (EHR) data with broader administrative claims data, enriched by de-identified clinical notes and diagnostic reports, such as radiology and pathology findings. This enables researchers to explore the narrative intricacies of patient care, including physician rationale, treatment strategies, and the subtleties of planning that are often disregarded in structured data alone.

Compliance with Regulatory Standards

The OMNY Foundation Oncology suite has also been meticulously crafted to adhere to the FDA's rigorous "Fit-for-Purpose" criteria, positioning it as a valuable resource for regulatory submissions and External Control Arms (ECAs). It boasts several key features:

1. Whole-Patient Visibility: This feature integrates oncology records with cardiovascular, metabolic, and primary care data, offering a complete view of pre-diagnosis history, comorbidities, and long-term survival outcomes.
2. Precision Variables: Direct access to detailed data such as tumor staging, treatment strategies, mutation data, and molecular biomarkers (including EGFR, ALK, PD-L1) enhances research depth.
3. Auditability and Provenance: A well-documented digital "paper trail" links every data point back to its source clinical event, ensuring transparency necessary for high-level regulatory evidence.
4. Integrated Outcomes: The suite includes pre-linked third-party administrative claims and mortality information to provide a holistic view of care delivery, treatment responses, and long-term survivorship.

Progressing from Big Data to Deep Data

Mitesh Rao, MD, CEO of OMNY Health, articulated the vision behind these advancements by stating, "Our goal is to transition the industry from 'big data' to 'deep data.' By encompassing the modern era of oncology screening and care across our extensive patient network, we deliver the scale of a national aggregator complemented by the clinical nuance typically found in specialty registries. The high-resolution evidence we provide is crucial for addressing today's most complicated medical questions."

About OMNY Health

OMNY Health serves as a leading healthcare data ecosystem, ensuring the secure exchange of clinical real-world data (RWD) and bridging gaps between healthcare providers and the life sciences sector. Alongside its recent introduction of the Oncology product suite, OMNY offers specialized RWD products across various therapeutic areas, including Dermatology, Ophthalmology, Gastroenterology, Respiratory, Cardiology, and Neurology.

For more insights and information, visit OMNY Health.